local_hospital

Sanos A/S

Address
lock Available on a paid plan

Cardiovascular Diseases

At Sanos A/S in Gandrup, a large share of the research focuses on cardiovascular diseases, especially atherosclerotic cardiovascular disease, hypertension, and conditions linked to elevated lipoprotein(a). These studies are designed to test new ways to reduce heart attack, stroke, and other major cardiovascular complications, while also improving prevention in people at high risk.

  • Testing treatments aimed at lowering cardiovascular risk in people with established disease or high-risk profiles
  • Studying therapies for elevated Lp(a) and related lipid disorders
  • Evaluating approaches to prevent major events such as myocardial infarction, stroke, and urgent revascularization

This area includes research on both prevention and long-term risk reduction, reflecting a strong emphasis on improving outcomes for people with serious heart and vascular disease.

Immune System Diseases

The site also conducts extensive trials in immune system diseases, with work centered on atopic dermatitis, psoriasis, rheumatoid arthritis, and polymyalgia rheumatica. These studies aim to better control inflammation, ease symptoms, and assess the safety and effectiveness of newer treatment options for chronic immune-mediated conditions.

  • Exploring therapies for atopic dermatitis, including long-term symptom control
  • Evaluating treatments for psoriasis and related inflammatory skin disease
  • Studying medicines for rheumatoid arthritis and polymyalgia rheumatica to improve disease control

Much of this research is focused on reducing disease activity and supporting durable treatment benefit in people living with persistent inflammatory disorders.

Musculoskeletal Diseases

A major research theme at Sanos A/S is musculoskeletal disease, particularly knee osteoarthritis, osteoarthritis, rotator cuff tendinopathy, and knee synovitis. These trials are aimed at finding better ways to relieve pain, improve function, and support joint health in people affected by chronic movement-related conditions.

  • Investigating treatments for knee osteoarthritis and associated pain
  • Assessing options to improve joint function and physical symptoms
  • Exploring approaches that may help protect or restore cartilage and joint structure

This field combines symptom relief with efforts to address the underlying burden of degenerative joint disease.

Nervous System Diseases

The research portfolio includes nervous system diseases such as migraine and Alzheimer’s disease. These studies are intended to improve prevention of migraine attacks, reduce headache burden, and assess new options for supporting people with neurodegenerative disease.

  • Studying preventive treatments for chronic migraine and episodic migraine
  • Evaluating therapies for early Alzheimer’s disease
  • Focusing on better symptom control and improved quality of life in neurological conditions

Overall, this area reflects a mix of symptom prevention and disease-focused research in conditions that can have a major impact on daily life.

Nutritional and Metabolic Diseases

Research in nutritional and metabolic diseases at this site is centered on obesity, overweight, type 2 diabetes, and related weight-management conditions. The trials are designed to evaluate new therapies that may help people lose weight, improve metabolic health, and lower the risk of complications linked to excess body weight.

  • Testing treatments for weight reduction in people with obesity or overweight
  • Studying therapies for type 2 diabetes and related metabolic risk
  • Assessing whether weight-focused treatments can also improve cardiovascular and joint outcomes

This area links metabolic health with broader disease prevention, including effects on the heart and joints.

Skin and Connective Tissue Diseases

The site runs trials in skin and connective tissue diseases such as acne vulgaris, vitiligo, pruritus, and atopic dermatitis. These studies are focused on improving skin symptoms, reducing visible disease burden, and testing new therapies for both inflammatory and chronic dermatologic conditions.

  • Evaluating treatments for acne vulgaris and other common skin conditions
  • Studying therapies for vitiligo and pruritus
  • Assessing options for long-term control of inflammatory skin disease

This research aims to improve both symptom relief and everyday well-being for people with chronic dermatologic disorders.

Virus Diseases

In the area of virus diseases, the research includes work related to the HPV vaccine and prevention of infections that can lead to cervical cancer and genital warts. The purpose of these studies is to better understand long-term protection and support public health prevention strategies.

  • Examining the effectiveness of HPV vaccination over time
  • Supporting prevention of HPV-related cancers and precancerous lesions
  • Contributing to broader infectious disease prevention efforts

This work adds a preventive dimension to the site’s portfolio, with emphasis on reducing future disease burden through vaccination research.

Site Overview

assignment
52
connected trials
corporate_fare
28
sponsors
science
48
IMPs

Activity Indicator

Last 6 months

7
Trials started
-22% vs previous period.
9
Trials started 6–12 months ago
52
Total trials linked
Highly Active
trending_downDeclining-22%
4
1
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 7 therapeutic areas and 15 of 48 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 42 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
19
Sponsors (total)
28
Active sponsors
12

Sponsor Network

Top 12 by active trials.

lock +11 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +9 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 111 other sites in Denmark

description
Trial volume
52
Outperforms 88% of sites
public
Therapeutic diversity
7areas
Outperforms 76% of sites
groups
Sponsor diversity
28sponsors
Outperforms 88% of sites

Therapeutic Area Benchmark — Denmark

Select a therapeutic area to compare against other sites in Denmark.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Denmark

Market Share

Country: Denmark

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Sanos A/S

lock Showing 1 of 52 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 1, Adaptive, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SYX-5219 in Healthy Volunteers and Participants with Atopic DermatitisSitryx Therapeutics LimitedPhase INot RecruitingJan 2026

IMP list

lock Showing 1 of 48 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Paracetamol6Unknown2023-02-032025-04-30

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.